Nisa Investment Advisors LLC Acquires 10,121 Shares of Guardant Health, Inc. $GH

Nisa Investment Advisors LLC grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 364.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,895 shares of the company’s stock after purchasing an additional 10,121 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Guardant Health were worth $2,300,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of GH. MCF Advisors LLC boosted its stake in shares of Guardant Health by 755.0% during the second quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after purchasing an additional 151 shares in the last quarter. NFSG Corp purchased a new position in Guardant Health during the third quarter valued at approximately $33,000. Ascentis Independent Advisors bought a new position in Guardant Health in the first quarter worth approximately $38,000. Hollencrest Capital Management bought a new position in Guardant Health in the first quarter worth approximately $41,000. Finally, TrinityBridge Ltd bought a new position in Guardant Health in the second quarter worth approximately $45,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Up 3.8%

GH opened at $169.08 on Friday. The company has a market cap of $22.69 billion, a P/E ratio of -48.45 and a beta of 1.58. The firm’s 50-day moving average price is $168.04 and its 200-day moving average price is $141.69. Guardant Health, Inc. has a 52-week low of $68.02 and a 52-week high of $191.05.

Guardant Health (NASDAQ:GH) last released its earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to analyst estimates of $314.23 million. The firm’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same quarter last year, the business earned ($0.44) earnings per share. On average, research analysts anticipate that Guardant Health, Inc. will post -3.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GH has been the topic of several recent research reports. Bank of America increased their target price on Guardant Health from $135.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Thursday, October 15th. Evercore reissued an “outperform” rating and issued a $200.00 price target on shares of Guardant Health in a research report on Monday, July 6th. Roth Capital initiated coverage on Guardant Health in a research report on Thursday. They issued a “buy” rating and a $200.00 price target for the company. Finally, Mizuho upped their price objective on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $190.40.

Insider Buying and Selling at Guardant Health

In related news, insider Terilyn J. Monroe sold 46,300 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total value of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares of the company’s stock, valued at $3,794,292.48. This represents a 66.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alex M. Azar II sold 826 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total value of $144,550.00. Following the completion of the transaction, the director owned 825 shares of the company’s stock, valued at $144,375. This trade represents a 50.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 178,940 shares of company stock valued at $30,070,911. Company insiders own 5.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.